Acute promyelocytic leukemia (APL) or M3 is a subtype of acute myeloid leukemia, according to the French-American-British group classification. High frequencies of APL have been reported previously by many investigators. We here studied AML patients to determine the frequency of APL in Tabriz in northwest Iran. We reviewed 483 AML patients from 1996-2003. M2 and M3 cases accounted for 43.4% and 19.4% of the total, respectively. Our study thus provides further evidence of high frequencies of APL associated with geographical areas. Further studies should now be performed to evaluate genetic and environmental predisposing factors in Iran.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In Vitro, In Vivo, Ex Vivo Characterisation of Dihydroimidazotriazinones and Their Thermal Decomposition Course Studied by Coupled and Simultaneous Thermal Analysis Methods.
Int J Mol Sci
January 2025
Laboratory of Bioorganic Compounds Synthesis and Analysis, Medical University of Lublin, 4A Chodźki Street, 20-093 Lublin, Poland.
The biological and thermal properties of a class of synthetic dihydroimidazotriazinones were disclosed in this article for the first time. Molecules --as potential innovative antimetabolites mimicking bicyclic aza-analogues of isocytosine-were evaluated for their in vitro anticancer activity. Moreover, in vivo, in vitro, and ex vivo toxicity profiles of all the compounds were established in zebrafish, non-tumour cell, and erythrocyte models, respectively.
View Article and Find Full Text PDFEvaluation of 3D-Printed Microfluidic Structures for Use in AML-Specific Biomarker Detection of PML::RARA.
Int J Mol Sci
January 2025
Department Hamm 1, Hamm-Lippstadt University of Applied Science, 59063 Hamm, Germany.
An obstacle for many microfluidic developments is the fabrication of its structures, which is often complex, time-consuming, and expensive. Additive manufacturing can help to reduce these barriers. This study investigated whether the results of a microfluidic assay for the detection of the promyelocytic leukemia (PML)-retinoic acid receptor α (RARα) fusion protein (PML::RARA), and thus for the differential diagnosis of acute promyelocytic leukemia (APL), could be transferred from borosilicate glass microfluidic structures to additively manufactured fluidics.
View Article and Find Full Text PDFUtilization of RT-PCR and Optical Genome Mapping in Acute Promyelocytic Leukemia with Cryptic Rearrangement: A Case Discussion and Systemic Literature Review.
Genes (Basel)
December 2024
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
Background: Acute promyelocytic leukemia (APL) is characterized by abnormal promyelocytes and t(15;17)(q24;q21) . Rarely, patients may have cryptic or variant rearrangements. All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) is largely curative provided that the diagnosis is established early.
View Article and Find Full Text PDF[Survival in Patients with Acute Myeloid Leukemia: A Survival Analysis of 120 Patients with Acute Myeloid Leukemia with a Focus on Patients Over 60 Years of Age at Sótero del Río Hospital].
Rev Med Chil
September 2024
Departamento de Hematología, Hospital Sótero del Río, Santiago, Chile.
Unlabelled: Acute myeloid leukemia (AML) is the most frequent type of leukemia in adults and has a high mortality burden. Patients over 60 years of age infrequently receive high-intensity chemotherapy.
Aim: To describe the clinical characteristics and evaluate the survival in patients with AML, focusing on patients over 60 years.
Acute promyelocytic leukemia with fusion potentially responds to all-trans retinoic acid/arsenic trioxide treatment.
Haematologica
January 2025
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; Chinese Institutes for Medical Research, Beijing.
Not available.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!